Dicot Pharma invites to an investor presentation on October 13
Uppsala October 7, 2026. Dicot Pharma AB invites shareholders and other investors to a webcast investor presentation to share the results from three abstracts being presented at the 27th Annual Fall Scientific Meeting, organized by the Sexual Medicine Society of North America (SMSNA) in Orlando, USA. The scientific conference, which takes place October 8–11, cannot be followed remotely. Therefore, Dicot Pharma will repeat the presentations during a webcast on October 13 at 3:00 p.m. CET.
During the investor presentation, the company’s CEO, Elin Trampe, and Head of Research, Charlotta Gauffin, will be present in the studio. Presentations in English will be delivered via link by Harin Padma-Nathan, MD, an internationally recognized expert in sexual medicine, and Arthur Burnett, MD, Professor of Urology at Johns Hopkins School of Medicine.
The webcast is open to everyone via this link and also on the company website and can also be viewed later.
The presentation will be available on the company’s website afterward.
The titles of the abstracts are:
“LIB-01: Part I - Durable Pro-Erectile Effects Involving Transcriptional Modulation of the Melanocortin System”. Presented by: Charlotta Gauffin, PhD, CSO Dicot Pharma.
“LIB-01: Part II - A Novel First-in-Class Oral Investigational Therapy for Erectile Dysfunction with Demonstrated Clinically Meaningful Improvements in Erectile Function and Duration of Action up to 8 Weeks”. Presented by: Dr. Harin Padma-Nathan.
“LIB-01: Part III - A Phase 2b Trial Design Adapted to a Molecule with a Novel Mechanism and Durable Pharmacodynamic Profile”. Presented by: Prof. Dr. Arthur Burnett.
For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicotpharma.com
About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma’s business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market.
Dicot Pharma is listed on Nasdaq First North and has approximately 17,450 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.
This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.